EDAP TMS S.A. Announces $7.5 Million Placement Lyon, France, July 27, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) announced that it has entered into a securities purchase agreement with selected accredited investors pursuant to which an aggregate of 961,676 of the company's ordinary shares in the form of

Ablatherm-HIFU experience highlighted by UK Prostate Cancer Charity The Prostate Cancer Charity , the largest and most comprehensive charity in the UK focused on prostate cancer, recently included a 4-page detailed overview of HIFU treatment for localized prostate cancer in its widely distributed

Second Fixed RPP Site Launched; To Treat First Indication and Radiation Failure Patients

Continued Interest from Leading Urologists; Growing Treatment Activity and Referrals

Subsidiary Formed in Response to Market Success, Ongoing Expansion Leipzig Site Launches Fixed RPP Model with Contract Commitment

Ablatherm Peer Reviewed Data Featured on Top Urology Reference Site EDAP and Ablatherm-HIFU were again featured in an email distributed by UroToday.com to more than 14,000 urologists advising them of the site's HIFU Resource Center. Urotoday.com, located at http://www.urotoday.com , is one of the

Ablatherm-HIFU featured on Euronews Video Broadcast EDAP and the Ablatherm-HIFU were featured on June 24 in a Euronews video segment. Euronews is a video broadcast network covering more than 120 million households in Europe, Canada and Southeast Asia. The video is linked here  for your viewing with